Latest News

Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec, a First-in-Class Antibiotic for the Treatment of Tuberculosis

SEONGNAM-SI, Korea--(BUSINESS WIRE)-- #Antibiotic--Qurient announced the publication in NEJM of positive results from the Phase 2 clinical trial for telacebec for the treatment of tuberculosis (TB).

Source link

Related posts

‘Locked down’ hospital ignores some infection control procedures


A direct link established between chronic insomnia and cognitive problems


What are the benefits of nature play for children?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy